Top Page
Pro Medicus Limited
(Sydney:PME)
Pro Medicus Limited (PME) vs. iShares MSCI Australia ETF (EWA)
Pro Medicus Limited Business Overview & Revenue Model
Pro Medicus Limited Earnings Call Summary
Pro Medicus Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 212.98M | 212.91M | 161.43M | 124.90M | 93.46M | 67.88M |
| Gross Profit | 169.16M | 212.60M | 122.24M | 92.36M | 92.94M | 46.66M |
| EBITDA | 170.62M | 164.85M | 120.69M | 91.69M | 69.64M | 49.53M |
| Net Income | 115.22M | 115.22M | 82.79M | 60.65M | 44.44M | 30.85M |
Balance Sheet | ||||||
| Total Assets | 338.70M | 338.70M | 257.43M | 202.13M | 157.05M | 125.57M |
| Cash, Cash Equivalents and Short-Term Investments | 209.19M | 209.19M | 154.89M | 121.50M | 90.55M | 61.82M |
| Total Debt | 2.25M | 2.25M | 2.07M | 1.85M | 2.28M | 2.62M |
| Total Liabilities | 81.74M | 81.74M | 69.70M | 63.36M | 55.32M | 43.89M |
| Stockholders Equity | 256.96M | 256.96M | 187.73M | 138.78M | 101.73M | 81.68M |
Cash Flow | ||||||
| Free Cash Flow | 118.43M | 103.95M | 80.08M | 58.33M | 53.20M | 31.33M |
| Operating Cash Flow | 118.87M | 111.33M | 86.78M | 64.77M | 62.23M | 39.02M |
| Investing Cash Flow | -14.12M | -6.58M | -78.07M | -9.79M | -17.56M | -27.40M |
| Financing Cash Flow | -57.62M | -57.62M | -39.84M | -27.53M | -23.31M | -14.05M |
Pro Medicus Limited Technical Analysis
Pro Medicus Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $26.02B | 225.79 | 50.70% | 0.22% | 31.88% | 39.10% | |
64 Neutral | AU$126.24M | 78.33 | 1.89% | ― | 10.06% | ― | |
55 Neutral | AU$74.13M | -8.12 | -8647.54% | ― | 25.98% | 22.10% | |
52 Neutral | AU$23.25M | -12.89 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$118.66M | ― | -12.35% | ― | 15.99% | 22.05% | |
40 Underperform | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% |
Pro Medicus Limited Corporate Events
Pro Medicus Limited has addressed recent speculation regarding a data breach involving Visage Imaging. The company confirmed that an unauthorized access incident occurred in July 2025, affecting a single email inbox, but no client systems or patient data were compromised. The breach was contained, and external cybersecurity experts were engaged. While some personal information of approximately 100 employees might have been accessed, no financial loss or operational impact was reported. Pro Medicus has informed affected individuals and relevant authorities, ensuring compliance with legal obligations.
Pro Medicus Limited has secured a $25 million, 7-year contract with BayCare, a leading healthcare system in Florida, to implement its Visage 7 Open Archive in the cloud. This deal extends their existing contract to a full-stack solution, enhancing Pro Medicus’s expansion into the North American IDN market and offering potential financial upside through a transaction-based model.
Pro Medicus Limited held its Annual General Meeting on November 24, 2025, where all resolutions on the agenda were successfully carried. Key resolutions included the approval of the remuneration report and the re-election of board members, indicating strong shareholder support and stability in the company’s governance.
Pro Medicus Limited reported a successful year both operationally and financially, attributing its achievements to its robust business model and the dedication of its staff. The company secured several new contracts, including its largest to date with Trinity Health, and continues to expand its product offerings through strategic acquisitions and licensing, strengthening its market position in North America and Germany.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has signed three new contracts valued at a minimum of A$29 million, expanding its presence in the healthcare imaging market. These contracts, which are cloud-based and transaction-oriented, involve a pediatric hospital, a cancer center, and a regional healthcare provider, highlighting the company’s adaptability across various segments. This development increases the company’s total contract value for the first half of FY26 to A$273 million, reinforcing its strong market position and future growth potential.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has secured a significant 5-year, A$44M contract with Advanced Radiology Management, a prominent private radiology group. This agreement involves implementing the cloud-based Visage 7 Enterprise Imaging Platform, which aims to enhance diagnostic interpretation efficiency. The rollout is set to begin immediately, with the platform expected to go live by late Q2 2026. This contract underscores Pro Medicus’s growing influence in the North American healthcare IT market and addresses the increasing demand for efficient radiology solutions amid a global shortage of radiologists.
Pro Medicus Limited has announced a daily update on its ongoing on-market buy-back program, with a total of 3,915 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial health.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 31,086 ordinary fully paid securities, including 3,904 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Pro Medicus Limited has announced an update regarding its ongoing buy-back program, detailing the acquisition of 3,865 ordinary fully paid securities on the previous day, bringing the total bought back to 23,317. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, with a recent acquisition of 3,924 ordinary fully paid securities. This buy-back strategy is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value, reflecting a strategic move to optimize financial performance and market positioning.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of November 11, 2025, the company has repurchased a total of 19,393 ordinary fully paid securities, including 3,902 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of the latest notification, the company has repurchased a total of 11,559 ordinary fully paid securities, with 3,911 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Pro Medicus Limited has announced its Annual General Meeting (AGM) scheduled for November 24, 2025, which will be conducted as a hybrid meeting. Shareholders can participate in person or online, with provisions made for voting and asking questions through a dedicated portal. This meeting is crucial for stakeholders to engage with the company’s board and discuss resolutions, reflecting Pro Medicus’s commitment to transparency and shareholder engagement.
Pro Medicus Limited has secured a 5-year, A$10 million contract to implement its Visage 7 Enterprise Imaging Platform at University Hospital Heidelberg and the German Cancer Research Institute, among other associated hospitals. This deal expands Pro Medicus’s presence in the European market, replacing and consolidating existing legacy systems to enhance diagnostic and research capabilities, thereby supporting cutting-edge medical research and patient care.
Pro Medicus Limited announced that it is not affected by the recently announced US tariffs on pharmaceuticals, as the company does not engage in the production or sale of pharmaceutical products. This clarification ensures that Pro Medicus’s operations remain unaffected by these tariffs, maintaining its focus on providing cutting-edge medical imaging solutions without any direct implications from the pharmaceutical industry tariffs.